Results 11 to 20 of about 113,548 (277)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma [PDF]

Frontiers in Cell and Developmental Biology, 2020
Histone deacetylases (HDACs) are enzymes that play a key role in regulating gene expression by remodeling chromatin structure. An imbalance of histone acetylation caused by deregulated HDAC expression and activity is known to promote tumor progression in
Monica Phimmachanh, Jeremy Z. R. Han, Yolande E. I. O’Donnell, Sharissa L. Latham, Sharissa L. Latham, David R. Croucher, David R. Croucher   +6 more
doaj   +3 more sources

Macrocyclic Histone Deacetylase Inhibitors [PDF]

Current Topics in Medicinal Chemistry, 2010
Histone deacetylase inhibitors (HDACi) are an emerging class of novel anti-cancer drugs that cause growth arrest, differentiation, and apoptosis of tumor cells. In addition, they have shown promise as anti-parasitic, anti-neurodegenerative, anti-rheumatologic and immunosuppressant agents. To date, several structurally distinct small molecule HDACi have
Sandra C, Mwakwari, Vishal, Patil, William, Guerrant, Adegboyega K, Oyelere   +3 more
openaire   +2 more sources

Non-Hydroxamate Histone Deacetylase Inhibitors [PDF]

Current Medicinal Chemistry, 2005
A number of histone deacetylase (HDAC) inhibitors have been developed as anticancer agents and most of them are hydroxamic acid derivatives, typified by suberoylanilide hydroxamic acid (SAHA), Trichostatin A (TSA) and NVP-LAQ824. However, hydroxamic acids have been associated with poor pharmacokinetics and severe toxicity. In addition, although isozyme-
Takayoshi, Suzuki, Naoki, Miyata
openaire   +2 more sources

Histone deacetylase inhibitors

Clinical Journal of Oncology Nursing, 2013
Histone deacetylase inhibitors (HDAC-Is) are agents that have demonstrated anticancer activity in vivo and in vitro, leading to clinical trials evaluating their efficacy in multiple cancer types. Only two HDAC-Is are currently approved by the U.S.
Claudia E. Rübe, Bernadine R. Donahue, Jay S. Cooper, Caspian Oliai, Yan Yu, Laura Doyle, Rene Rubin, Darek Michalski, M. Saiful Huq, Filip T. Troicki, Jaganmohan Poli, Carlos A. Perez, Wade L. Thorstad, Filip T. Troicki, Jaganmohan Poli, Lindsay G. Jensen, Brent S. Rose, Arno J. Mundt, Lindsay G. Jensen, Brent S. Rose, Arno J. Mundt, Lindsay G. Jensen, Brent S. Rose, Arno J. Mundt, Lindsay G. Jensen, Brent S. Rose, Arno J. Mundt, Caspian Oliai, Lindsay G. Jensen, Brent S. Rose, Arno J. Mundt, Filip T. Troicki, Jaganmohan Poli, Anthony E. Dragun, Rene Rubin, Stephan Mose, Christin A. Knowlton, Michelle Kolton Mackay, Bradley J. Huth, Claus Roedel, Stephan Mose, Stephan Mose, Erik Limbergen, Brandon J. Fisher, Larry C. Daugherty, Rene Rubin, Tod W. Speer, Hans-Peter Heilmann, Theodore E. Yaeger, Rene Rubin, Feng-Ming Kong, Jingbo Wang, Christin A. Knowlton, Michelle Kolton Mackay, Patrizia Guerrieri, Paolo Montemaggi, Gerhard G. Grabenbauer, Stephan Mose, Tod W. Speer, Patrizia Guerrieri, Paolo Montemaggi, Volker Budach, Carsten Nieder, Talha Shaikh, Jacqueline Emrich, Lydia T. Komarnicky-Kocher, Darek Michalski, M. Saiful Huq, Ramesh Rengan, Charles R. Thomas, Christin A. Knowlton, Michelle Kolton Mackay   +71 more
  +5 more sources

Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo [PDF]

, 2013
Targeted drugs have significantly improved the therapeutic options for advanced renal cell carcinoma (RCC). However, resistance often develops, negating the benefit of these agents.
Bartsch, Georg, Blaheta, Roman A., Haferkamp, Axel, Jüngel, Eva, Makarević, Jasmina, Nelson, Karen, Tsaur, Igor   +6 more
core   +10 more sources

Histone Deacetylase Inhibitors: A Novel Strategy for Neuroprotection and Cardioprotection Following Ischemia/Reperfusion Injury

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
Ischemia/reperfusion injury is a complex molecular cascade that causes deleterious cellular damage and organ dysfunction. Stroke, sudden cardiac arrest, and acute myocardial infarction are the most common causes of ischemia/reperfusion injury without ...
Zachary Pickell, Aaron M. Williams, Hasan B. Alam, Cindy H. Hsu   +3 more
doaj   +1 more source

Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas

Haematologica, 2018
Histone deacetylase inhibitors are promising agents for various T-cell lymphomas, including cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and adult T-cell lymphoma/leukemia. CCR4 is an important therapeutic target molecule because mogamulizumab,
Akihiro Kitadate, Sho Ikeda, Fumito Abe, Naoto Takahashi, Norio Shimizu, Kosei Matsue, Hiroyuki Tagawa   +6 more
doaj   +1 more source

Histone deacetylase 2-mediated deacetylation of the Ribonuclease 1 promoter in inflamed human endothelial cells [PDF]

, 2020
Endothelial cells (ECs) function as protective barrier to separate the blood from the surrounding tissue by conducting crucial roles in regulation and maintenance of vascular homeostasis, such as control of vessel permeability or coagulation.
Bedenbender, Katrin
core   +1 more source

Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity [PDF]

, 2016
Background: Histone deacetylase inhibitors (HDACi) exert multiple cytotoxic actions on cancer cells. Currently, different synthetic HDACi are in clinical use or clinical trials; nevertheless, since both pro-invasive and anti-invasive activities have been
Andrade, Ricardo, Arluzea, Jon, Aréchaga, Juan, De Wever, Olivier, Díaz-Núñez, María, Díez-Torre, Alejandro, Silió, Margarita   +6 more
core   +4 more sources

Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer [PDF]

, 2016
Introduction: In developed countries, ovarian cancer is the fourth most common cancer in women. Due to the nonspecific symptomatology associated with the disease many patients with ovarian cancer are diagnosed late, which leads to significantly poorer ...
A Hayashi, A Mai, A Saito, A Vannini, A Villar-Garea, AA Lane, AJ Dembo, AJ Wilson, Albandri Alfraidi, AM Abukhdeir, Aun Muhammad, AW Kurian, B Sorbe, BA Goff, BD Strahl, BH Huang, BY Karlan, C Aghajanian, C Bosetti, C Campas-Moya, C Gomez-Raposo, CJ Dunton, CM Grozinger, CS Marcus, CT Lin, D Khabele, D Matei, D Mottet, D Strumberg, D Waltregny, DC Drummond, DD Bowtell, DE Marsden, DK Armstrong, DM Dinulescu, Dmitri Pchejetski, DO Bauerschlag, E Hu, E Smolle, E Verdin, G Piperno, G Tortolero-Luna, H Naora, HA Risch, Heba Alshaker, HL Cheng, I Cetin, IK Kolasa, J Boyd, J Morrison, J Permuth-Wey, J Plisiecka-Halasa, J Prat, J Sonnemann, J Zhang, JA Rauh-Hain, JE Bolden, JE Palmer, JF Stratton, JH Choi, JJ Hwang, JL Benedet, JL MacDonald, JL Walker, JM Piek, JP Secrist, JR Graff, JR Ribeiro, K Kudoh, K Ozaki, K Sawada, K Struhl, KA Lowe, KB Glaser, Keith Sacco, KF McGonigle, KR Cho, L Dai, Leonardo Monzon, M Booth, M Fung-Kee-Fung, M Kartalou, M Markman, M Ohmichi, M Schuijer, MF Fathalla, MJ Piccart, MJ Scanlan, MK Tuxen, ML Friedlander, MM Leitao, MS Finnin, MS Kim, N Einhorn, N Einhorn, N Takai, N Takai, N Takai, NC Hait, NG Gavalas, NS Bese, P Marks, P Zhu, PH Wang, R Furumai, RA Burger, RA Burger, RC Bast Jr, RF Ozols, RL Coleman, RP Warrell Jr, RP Wernyj, S Gregoire, S Rinaldi, S Senese, S Spiegel, SA Cannistra, SA Gayther, SA Gayther, SC Modesitt, SR Wedge, T Meyer, TJ Herzog, TJ Perren, TL Klug, V Auner, V Conteduca, W Fischle, W Weichert, X Qian, YV Shebzukhov   +130 more
core   +1 more source